<DOC>
	<DOCNO>NCT00441467</DOCNO>
	<brief_summary>Primary Objective : 1 . To evaluate efficacy glufosfamide subject advance soft tissue sarcoma measure objective response rate Secondary Objectives : 1 . To evaluate efficacy glufosfamide subject advance soft tissue sarcoma measure duration response , progression-free survival overall survival 2 . To evaluate safety glufosfamide subject advance soft tissue sarcoma Exploratory Objectives : 1 . To evaluate biological effect glufosfamide metabolic profile subject advance soft tissue sarcoma , determine FDG-PET 2 . To correlate efficacy endpoint expression tumor-associated glucose transporter protein</brief_summary>
	<brief_title>Safety Efficacy Study Glufosfamide Previously Treated Advanced Soft Tissue Sarcoma</brief_title>
	<detailed_description />
	<mesh_term>Sarcoma</mesh_term>
	<mesh_term>Ifosfamide</mesh_term>
	<criteria>At least 18 year age Ability understand purpose risk study sign write informed consent form approve investigator 's IRB/Ethics Committee Pathologically confirm diagnosis soft tissue sarcoma Locally advance unresectable metastatic disease standard curative therapy available progress since recent therapy Measurable disease RECIST criteria least one target lesion 1 2 prior chemotherapy/systemic therapy regimen advance disease Eastern Cooperative Oncology Group ( ECOG ) Performance Status score 0 , 1 2 A minimum 3 week prior chemotherapy , radiation therapy , immunotherapy , antitumor therapy study entry Recovered reversible toxicity prior therapy Hemoglobin ≥ 9.0 g/dL , neutrophils ≥ 1,500/µL , platelet ≥ 100,000/µL Total bilirubin ≤ 1.5fold ULN , AST/ALT ≤ 2.5fold ULN ( ≤ 5fold liver metastasis ) Normal creatinine clearance ( ≥85 mL/min men ≥75 mL/min woman ; calculate CockcroftGault formula All woman childbearing potential must negative serum pregnancy test subject must agree use effective mean contraception ( surgical sterilization use barrier contraception either condom diaphragm conjunction spermicidal gel IUD ) entry study 6 month last dose Soft tissue sarcoma follow subtypes : gastrointestinal stromal tumor ( GIST ) , alveolar soft part sarcoma , hemangiopericytoma Kaposi 's sarcoma Most recent relapse occur treatment ifosfamide within 4 week last dose Symptomatic brain leptomeningeal metastasis Active clinically significant infection require antibiotic Recent ( one year ) history symptom cardiovascular disease ( NYHA Class 2 , 3 , 4 ) , particularly coronary artery disease , arrhythmias conduction defect risk cardiovascular instability , uncontrolled hypertension , clinically significant pericardial effusion , cerebrovascular accident congestive heart failure Previously treat malignancy , except adequately treat nonmelanoma skin cancer , situ cancer , cancer subject diseasefree least 5 year Major surgery within 3 week start study treatment , without complete recovery Females pregnant breastfeed Participation investigational drug device study within 21 day study entry Concomitant disease condition could interfere conduct study , opinion investigator would pose unacceptable risk subject study Unwillingness inability comply study protocol reason</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2015</verification_date>
</DOC>